Jade Biosciences prices 3.21M shares at $14.00 in private placement

Jade Biosciences (JBIO) entered into a securities purchase agreement with BB Biotech (BBAGF) for a private placement financing that is expected to result in gross proceeds of approximately $45M to the Company, before offering expenses. Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of 3,214,286 shares of its common stock at a purchase price of $14.00 per share. The private placement is expected to close on or about December 16, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement to fund research and development, general corporate expenses, and working capital needs.